Eupraxia Pharmac Stock Price, News & Analysis

Eupraxia Pharmaceuticals (NASDAQ:EPRX), a clinical-stage biotech company, has announced its participation in four upcoming investor conferences in August and September 2025. The company, which specializes in DiffuSphere™ technology for optimized local drug delivery, will present at the Canaccord Growth Conference (August 12-14), Citi Biopharma Conference (September 2-3), Cantor Global Healthcare Conference (September 3-5), and H.C. Wainwright Global Investment Conference (September 8-10).

The presentations will take place in Boston and New York, with scheduled times at 9:30am ET on August 13 at Canaccord and 9:10am ET on September 5 at Cantor.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) has initiated the Phase 2b placebo-controlled portion of its RESOLVE clinical trial for EP-104GI, a treatment for eosinophilic esophagitis (EoE). The study will enroll minimum 60 patients across 25 global sites, evaluating two active doses against placebo over 12 months.

The trial's first active dose of 120 mg was selected based on encouraging early data from cohort 8, showing the largest decline in Peak Eosinophil Count and lowest EoEHSS scores at 4 weeks. The study will assess tissue health, symptom scores, and safety, with placebo patients eligible to receive EP-104GI after six months. Topline data is expected by Q3 2026, with additional Phase 2a data releases planned for September and November 2025.

Eupraxia Pharmaceuticals (TSX/NASDAQ: EPRX) held its Annual General and Special Meeting on June 2, 2025, where shareholders approved all proposed items. All six board nominees were successfully elected with high approval rates, led by James A. Helliwell and Joseph Freedman with 99.997% votes in favor. Shareholders also approved the appointment of KPMG LLP as auditors, the 2025 Omnibus Incentive Plan, and the re-pricing of certain non-executive employee stock options. Eupraxia is advancing its DiffuSphere™ technology platform, designed for targeted drug delivery with extended-release capabilities. The company has two key clinical programs: EP-104GI in Phase 1b/2a for EoE treatment and EP-104IAR, which recently completed a successful Phase 2b trial for knee osteoarthritis pain, meeting its primary endpoint and three secondary endpoints.

Eupraxia Pharmaceuticals (NASDAQ/TSX: EPRX) has announced a virtual Key Opinion Leader (KOL) event scheduled for May 9, 2025, at 9:00 AM ET. The event will feature Dr. Evan Dellon from the University of North Carolina, Chapel Hill, alongside company management to discuss additional clinical data from the Phase 1b/2a RESOLVE Study of EP-104GI for treating eosinophilic esophagitis (EoE).

Dr. Dellon will join CEO Dr. James Helliwell to explore the unmet needs in EoE treatment, current treatment landscape, and how the RESOLVE study's safety and efficacy data suggests EP-104GI's potential to become a new standard of care. The event will conclude with a Q&A session.

Eupraxia Pharmaceuticals (NASDAQ/TSX: EPRX) reported its Q1 2025 financial results and provided updates on its EP-104GI clinical trial for Eosinophilic Esophagitis (EoE). The company highlighted positive nine-month data from the Phase 1b/2a RESOLVE trial, showing sustained treatment outcomes with a single 48mg dose. Financial results showed a net loss of $6.8 million compared to $6.2 million in Q1 2024. The company maintains a strong cash position of $27.5 million as of March 31, 2025, with runway extending to Q3 2026. Key developments include the appointment of Alex Rothwell as CFO and continued positive trial results with no serious adverse events reported. The company is monitoring potential impacts of proposed U.S.-Canada tariffs on its operations.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported sustained positive outcomes from its RESOLVE Phase 1b/2a trial of EP-104GI for eosinophilic esophagitis (EoE) treatment. After 9 months, patients receiving 48mg EP-104GI showed sustained or improved treatment outcomes. Key findings include:

- All patients reported reduced symptom severity, with up to 100% reduction and average 65% improvement in SDI scores
- 56% reduction in tissue health (EoEHSS Stage) and 45% reduction in Grade score
- 77% mean decrease in eosinophil counts with 52% remission rate
- One patient maintained complete histologic remission from 3 through 9 months

The 6-month data for the 64mg cohort showed up to 86% reduction in symptom severity. The company plans to release additional long-term data with higher doses in Q3 2025.

Eupraxia Pharmaceuticals (NASDAQ/TSX:EPRX) has announced its participation in several key investor and scientific conferences during April and May 2025. The company will showcase research on two main products: EP-104IAR for knee osteoarthritis and EP-104GI for eosinophilic esophagitis (EoE).

At the OARSI World Congress in South Korea (April 24-27), Dr. Phil Conaghan will present findings on EP-104IAR's sustained pain response in knee osteoarthritis patients. The Digestive Disease Week in San Diego (May 3-6) will feature two presentations: Dr. Evan Dellon will discuss EP-104GI's Phase 1b/2a study results, while Dr. Amanda Malone will present on esophageal strictures epidemiology.

Additional presentations include CEO Dr. James Helliwell at the Bloom Burton & Co. Healthcare Investor Conference (May 5-6) in Toronto, and Dr. Arjan Bredenoord at the ESDE Annual Congress (May 11-13) in Amsterdam.

Eupraxia Pharmaceuticals (NASDAQ/TSX: EPRX) reported Q4 2024 financial results, highlighting positive developments in its clinical trials. The company posted a net loss of $7.5 million for Q4 2024, an improvement from the $10.6 million loss in Q4 2023. Cash position strengthened to $33.1 million as of December 31, 2024, up from $19.3 million year-over-year.

Key highlights include compelling data from the Phase 1b/2a RESOLVE trial for EP-104GI in treating eosinophilic esophagitis, with improved tissue health and symptom reduction outcomes at higher doses. The company successfully raised C$44.5 million through a private placement, extending its funding runway into Q3 2026.

The company is monitoring potential impacts of proposed 25% U.S. tariffs on Canadian goods and planned Canadian retaliatory tariffs, as it sources API and manufactures clinical supplies in the U.S.

Eupraxia Pharmaceuticals announced positive data from its RESOLVE Phase 1b/2a trial of EP-104GI for treating Eosinophilic Esophagitis (EoE), an inflammatory disease causing difficulty swallowing. The trial showed consistent improvements in histological scores and symptom relief as dosage and esophageal coverage increased.

Cohort 6 demonstrated the most significant results to date, with the greatest symptom relief scores at 12 weeks, largest improvements in tissue health scores, and highest reduction in Peak Eosinophil Count. Cohort 5 showed the greatest symptom score reduction at 24 weeks, with continuously improving relief over time.

Notably, a clear dose-response was observed from Cohorts 3 to 6, with no serious adverse events or oral/gastrointestinal candidiasis reported across all six cohorts. The company believes EP-104GI could become a new standard of care for EoE treatment, with Cohort 7 fully enrolled and 12-week data expected in Q2 2025.